Uncategorized Archives - HealthCare Royalty Partners

June 30, 2022

Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners

June 16, 2022

Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million

June 24, 2021

Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million

March 31, 2021

Aptevo Therapeutics Announces Sale of Ruxience Royalty Payments to HCR

March 29, 2021

Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma

September 10, 2020

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

June 22, 2020

Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

June 9, 2020

Albireo Announces Two Financing Transactions to Extend Cash Runway Into the Beginning of 2022

June 1, 2020

First Meeting with Ted Seides: Interview with Clarke Futch – HealthCare Royalty Partners

May 12, 2020

COVID-19 Private Financing